Tolrestat acts atypically as a competitive inhibitor of the thermostable aldo‐keto reductase Tm1743 from Thermotoga maritima
Sign Up to like & getrecommendations! Published in 2019 at "FEBS Letters"
DOI: 10.1002/1873-3468.13630
Abstract: Tolrestat and epalrestat have been characterized as noncompetitive inhibitors of aldo‐ketone reductase 1B1 (AKR1B1), a leading drug target for the treatment of type 2 diabetes complications. However, clinical applications are limited for most AKR1B1 inhibitors… read more here.
Keywords: reductase; thermotoga maritima; tm1743 thermotoga; tm1743 ... See more keywords